文献速递腹部CT

靶向抗血管药物治疗神经内分泌肿瘤肝转移及正常肝脏的CT灌注表现

CT perfusion in normal liver and liver metastases from neuroendocrine tumors treated with targeted antivascular agents.
PubMed 文献 · Abdom Radiol (NY) · 2018-01-01

该回顾性研究纳入27例神经内分泌肿瘤肝转移患者,比较贝伐珠单抗单药、依维莫司单药及两药联合对肿瘤和正常肝脏CT灌注参数的影响。贝伐珠单抗单药显著降低肿瘤血容量,依维莫司单药对肿瘤CT灌注参数无影响;联合治疗后两组肿瘤血容量和血流量均较基线显著降低,依维莫司组渗透表面积乘积显著降低。正常肝脏中两药单药均无显著影响,联合治疗后依维莫司组血容量、平均通过时间和渗透表面积乘积显著降低、肝动脉分数升高,贝伐珠单抗组仅渗透表面积乘积降低。

要点

  • 贝伐珠单抗单药可显著降低神经内分泌肿瘤肝转移灶的血容量(p=0.05)
  • 依维莫司单药对肿瘤CT灌注参数无显著影响
  • 联合治疗后两组肿瘤血容量和血流量均较基线显著降低(p≤0.04)

核心结论

  • 贝伐珠单抗和依维莫司单药及联合对神经内分泌肿瘤肝转移灶和正常肝脏的CT灌注参数有显著且不同的影响,且在开始治疗后早期即可显现;CT灌注可能为无创评估药物对肿瘤和正常组织效应提供手段。

研究设计与样本

  • 回顾性研究,纳入27例可评估的神经内分泌肿瘤肝转移患者,来自一项双臂随机临床试验,分别接受贝伐珠单抗单药(B组)或依维莫司单药(E组)治疗3周后联合两种靶向药物。

关键影像表现/征象

  • 肿瘤中贝伐珠单抗单药显著降低血容量(p=0.05),依维莫司单药对CT灌注参数无影响。
  • 联合治疗后两组肿瘤血容量和血流量均较基线显著降低(p≤0.04),E组渗透表面积乘积显著降低(p<0.0001)。
  • 正常肝脏中两药单药对CT灌注参数均无显著影响。
  • 联合治疗后E组正常肝脏血容量、平均通过时间和渗透表面积乘积较基线显著降低、肝动脉分数升高(p≤0.04),B组仅渗透表面积乘积降低(p=0.04)。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

英文原文(摘要)· 点击展开

OBJECTIVE: To assess the effects of bevacizumab and everolimus, individually and combined, on CT perfusion (CTp) parameters in liver metastases from neuroendocrine tumors (mNET) and normal liver.

METHODS: This retrospective study comprised 27 evaluable patients with mNETs who had participated in a two-arm randomized clinical trial of mono-therapy with bevacizumab (Arm B) or everolimus (Arm E) for 3 weeks, followed by combination of both targeted agents. CTp was undertaken at baseline, 3 and 9 weeks, to evaluate blood flow (BF), blood volume (BV), mean transit time (MTT), permeability surface area product (PS), and hepatic arterial fraction (HAF) of mNET and normal liver, using a dual-input distributed parameter physiological model. Linear mixed models were used to estimate and compare CTp parameter values between time-points.

RESULTS: In tumor, mono-therapy with bevacizumab significantly reduced BV (p = 0.05); everolimus had no effects on CTp parameters. Following dual-therapy, BV and BF were significantly lower than baseline in both arms (p ≤ 0.04), and PS was significantly lower in Arm E (p < 0.0001). In normal liver, mono-therapy with either agent had no significant effects on CTp parameters: dual-therapy significantly reduced BV, MTT, and PS, and increased HAF, relative to baseline in Arm E (p ≤ 0.04); in Arm B, only PS reduced (p = 0.04).

CONCLUSIONS: Bevacizumab and everolimus, individually and when combined, have significant and differential effects on CTp parameters in mNETs and normal liver, which is evident soon after starting therapy. CTp may offer an early non-invasive means to investigate the effects of drugs in tumor and normal tissue.

来源:Abdom Radiol (NY),查看原文。版权归原作者所有。

引用

  1. Ng CS, Wei W, Duran C, et al. CT perfusion in normal liver and liver metastases from neuroendocrine tumors treated with targeted antivascular agents. Abdom Radiol (NY). 2018. PMID: 29075824. doi:10.1007/s00261-017-1367-1

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。